Modeling the hepatitis C virus epidemic in france
β Scribed by Sylvie Deuffic; Laurent Buffat; Thierry Poynard; Alain-Jacques Valleron
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 227 KB
- Volume
- 29
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
β¦ Synopsis
A backcalculation approach allows a reconstruction of the history of hepatitis C virus (HCV) infection in France and predictions of mortality from hepatocellular carcinoma (HCC) related to the virus. The model uses information from the literature about the natural history of the disease, epidemiological data about infected subjects in three French cohorts, and mortality data from national statistics. It seeks to determine the annual transition probabilities from chronic hepatitis to cirrhosis and the HCV incidence per year in the past. These unknowns are found by fitting the observed deaths from HCC that are attributable to HCV. Optimal values for these unknowns then allow to project the number of HCC deaths attributable to HCV for each year through 2025 (for patients infected before 1996). The model traces the HCV epidemic in France back to around the 1940s. It predicts that HCC mortality related to HCV will continue to increase through 2020 in the absence of treatment, with a 150% increase in the yearly incidence among men and 200% among women. The model also confirms that progression to cirrhosis depends strongly on sex and age. At any age, the annual probability of progression is 10 times greater for men than for women. Moreover, for men aged between 61 and 70 years, this probability is 300 times greater than that for men aged between 21 and 40 years. (HEPATOLOGY 1999;29:1596-1601.)
Abbreviations: HCV, hepatitis C virus; HCC, hepatocellular carcinoma; AIDS, acquired immune deficiency syndrome.
π SIMILAR VOLUMES
The putative role of hepatitis C virus (HCV) infection in the pathophysiology of lymphoproliferative diseases (LPD) is supported by North American and southern European studies reporting high HCV seroprevalence in patients with B-cell-non-Hodgkin lymphoma (NHL). In order to evaluate the situation in
Our knowledge of hepatitis C virus (HCV) dates only from by several groups, thereby establishing that it was caused by a transmissible agent. The chimpanzee provided a means of 1975, when non-A, non-B hepatitis was first recognized. It was not until 1989 that the genome of the virus was first charac
The study of hepatitis C virus (HCV), a major cause of chronic liver disease, has been hampered by the lack of a cell culture system